tbuckley/cabot-search huggingface dataset:
Comorbidity and functional status are independent in older cancer patients.
Authors: M Extermann, J Overcash, G H Lyman, J Parr, L Balducci
Journal: Journal of Clinical Oncology (1998)

PURPOSE Comorbidity is a frequent and often therapeutically limiting problem in older cancer patients. However, to date, there is no standard measure of the comorbidity burden available for these patients. We tested the performance of two comorbidity scales and their relationship with functional status. PATIENTS AND METHODS The Cumulative Illness Rating Scale-Geriatric (CIRS-G) was compared with the Charlson scale in 203 patients who received a comprehensive geriatric assessment (CGA) in our Senior Adult Oncology Program (SAOP). Study end points were variability, reliability, correlation with Eastern Cooperative Oncology Group (ECOG) performance status (PS), Activities of Daily Living (ADL), and Instrumental Activities of Daily Living (IADL). The relative weight of comorbidity versus tumor stage in the correlations with functional status was assessed. RESULTS Median age was 75 years (range, 63 to 91). Sixty-four percent of patients scored 0 on the Charlson scale versus 6% on the CIRS-G. The correlation between the Charlson and CIRS-G was fair (p = 0.25 to 0.39). CIRS-G grade 3/4 had a fair correlation with ADL (p = 0.27). Otherwise, there was low or no correlation between comorbidity and functional status across the measures. Tumor stage was not correlated with functional status either. Correlation of ECOG PS with ADL (p = 0.51)c and IADL (p = 0.61) was moderate. Interrater and test-retest correlations were good or very good for both the Charlson and CIRS-G. CONCLUSION Comorbidity needs to be assessed independently from functional status. Both the Charlson and CIRS-G scales are reliable tools for use in trials of older cancer patients. Both can be tested in further studies as predictors of outcomes such as toxicity of treatment, changes in functional status, or survival.
Randomized phase II trial of concomitant CT/RT versus TPF followed by concomitant CT/RT in locally advanced squamous cell carcinoma of the head and neck (LASCCHN)
Authors: A. Paccagnella, A. Buffoli, H. Koussis, P. D’Amanzo, L. Loreggian, A. Bonetti, F. Valduga, A. Gava, A. Ardizzoia, C. Sguotti
Journal: Journal of Clinical Oncology (2006)

5518 Background: Concomitant CT/RT is the standard treatment for LASCCHN. Induction chemotherapy followed by CT/RT vs CT/RT alone have not yet been compared. The feasibility of TPF followed by CT/RT has been evaluated in a previous study (Int J Rad Oncol Biol Phys 2004, 59:481). Methods: Pts with inoperable stage III-IVa, PS 0–1, were randomized to CT/RT [2 cycles of Cisplatin 20 mg/sqm days 1–4, 5FU 800 mg/sqm 96 hours c.i. weeks 1 and 6 during RT (66–70 Gy)] (Arm A) or 3 cycles of neoadjuvant TPF (Docetaxel 75mg/sqm day1, Cisplatin 80mg/sqm day1, 5FU 800mg/sqm 96 hours c.i) followed by the same CT/RT (Arm B). Pts were stratified according to tumor site, T stage and nodal status. Neck dissection was performed in N2-N3 patients with pathological CR on primary tumor. The planned sample size was 96 pts to detect a difference in CR (primary endpoint) up to 15% in favour of arm B. The radiological responses were evaluated by an internal committee according to RECIST criteria. Results: Preliminary data are available for 84/96 randomized pts (42 arm A, 42 arm B). Pts/tumor characteristics are well balanced in the two arms. Toxicities during induction TPF consisted primarily of G3–4 granulocytopenia 56% (febrile neutropenia: 7.5%). Grade 3–4 toxicities during CT/RT in arm A and B were mucositis (42% and 26%), dysphagia (20% and 9%), skin reaction (12% and 8.6%), asthenia (5% and 3%); G3 weight loss (2% and 3%), G3 dry-mouth (0% and 3%). Duration of CT/RT was equivalent: 6.1 wks (4.2–8.7) in arm A and 6.3 wks (3.8–9.5) in arm B. At the end of CT/RT, in the 82 pts evaluable for efficacy, radiological CR were 20% (95% CI 8–37%) in arm A and 64% (95% CI 45–80%) in arm B. Conclusions: Three cycles of neoadjuvant TPF are feasible and don’t compromise subsequent concomitant CT/RT with comparable toxicity pattern. At the end of the treatment sequence serious adverse events were 31% in arm A and 34% in arm B. The difference in CR of 40% in favour of arm B justifies the following phase III study. Final results including pCR and DFS will be presented at the meeting. [Table: see text]
Reassessment of Cancer Predisposition of Fanconi Anemia Heterozygotes&lt;xref ref-type="fn" rid="FN2"&gt;2&lt;/xref&gt;&lt;xref ref-type="fn" rid="FN3"&gt;3&lt;/xref&gt;
Authors: Michael Swift
 5, Robin J. Caldwell, Charles Chase
Journal: JNCI Journal of the National Cancer Institute (1980)

The hypothesis that heterozygotes for the Fanconi anemia (FA) gene are predisposed to cancer was investigated by comparing the observed and expected numbers of cancer cases and deaths in 25 extended families of FA probands. This study demonstrated no overall excess of cancers of cancer deaths for any age or sex category of blood relatives and no unusual number of cancers among the obligate heterozygotes. Deaths from leukemia among blood relatives were fewer than expected. For bladder, stomach, and breast cancer there were more deaths and cases among blood relatives than expected, although the differences were not statistically significant. An excess of deaths at an early age from lung and stomach cancer was noted among the FA blood relatives. Among spouse controls there were fewer deaths than expected from bladder, stomach, and breast cancer; thus the expected numbers may be inappropriately high for this sample. Therefore, the question of predisposition to bladder, stomach, and breast cancer among FA heterozygotes remains unresolved.
Weekly docetaxel plus gemcitabine or vinorelbine in refractory advanced breast cancer patients: A parallel dose-finding study
Authors: G. Frasci, P. Cornella, G. D'Aiuto, R. Thomas, I. Capasso, M. Elmo, G. Botti, G.R. Cortino, L. Lapenta, V. De Rosa, P. Vallone, A. Petrillo, G. Cornella
Journal: Annals of Oncology (2000)
Importance of cancer-associated symptoms on prognosis of patients with metastatic renal cell carcinoma: A single-center experience
Authors: E. Llerena, K. Kancheff, J. L. Gonzalez-Vela, D. Hernandez, S. Treviño, D. Fierro, J. Martinez, R. Lopez, R. G. Najera, J. F. Gonzalez-Guerrero
Journal: Journal of Clinical Oncology (2005)

4801 Background: Metastatic renal cell carcinoma (mRCC) has a poor prognosis, but survival is quite different among different subgroups of patients, it doesn’t matter how they were treated. Some clinical and biochemical prognostic factors have been published. Objective: To evaluate the prognostic impact of cancer - related symptoms present at the diagnosis of mRCC. Methods: We analyzed the clinical records of patients with histologically confirmed mRCC who have been seen in our center from January 2000 to May 2004. Results: 43 patients with mRCC, 29 men and 14 female, the median age was 57 years (39–78y), the most common sites of metastases were bone (33%), lung (32%), retroperitoneal nodes (23%), liver (18%), brain (9%), soft tissue (9%) and other (<5%), most of the patients had two or more sites of metastases. 10/43 patients (23.2%), were asymptomatic at the diagnosis. 27 patients received specific oncologic treatment (immunotherapy, RT,CH) and 16 only symptomatic medication. 30 patients have died (69.7%). The median survival was 22 months in patients who were asymptomatic and 6.3 months in patients with symptoms (ECOG >1) at the diagnosis. 8/13 patients alive were asymptomatic at the diagnosis, their median survival is 23.7 months and only 4 (50%) received specific treatment (3RT,1CH). Conclusions: mRCC has an unpredictable evolution, only a minority of treated patients experience a favorable response with “standard” therapy, patients who are symptomatic at the diagnosis have the poorest survival, performance status (ECOG) is the strongest prognostic factor. No significant financial relationships to disclose.
Stem Cell Dysfunction Exacerbates Muscular Dystrophy
Authors: Tracy Hampton
Journal: JAMA (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Journals JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2024 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Abstract 17468: Barriers and Facilitators Associated with Utilization of Cardiac Rehabilitation Programs at VA Facilities
Authors: David W Schopfer, Amit Bhakhri, Kelly Allsup, Daniel E Forman, Mary A Whooley
Journal: Circulation (2012)

Background: Exercise-based cardiac rehabilitation (CR) programs reduce morbidity and mortality in patients with ischemic heart disease (IHD). Referral of patients with IHD to a CR program is a perf...
Absence of correlation between the molecular subtype of <i>COL1A1-PDGFB</i> fusion gene and the clinico-histopathological features of dermatofibrosarcoma protuberans: Analysis of 35 novel cases and review of 137 cases from the literature.
Authors: D. Giacchero, G. Maire, P. Nuin, J. Coindre, J. P. Lacour, F. Pedeutour
Journal: Journal of Clinical Oncology (2010)

10071 Background: The translocation t(17;22) resulting in COL1A1-PDGFB fusion gene is found in dermatofibrosarcoma protuberans (DFSP) and its clinico-pathological variants. The chimeric COL1A1-PDGFB transcript shows a great variability of the COL1A1 breakpoint from exon 6 to exon 49, contrasting with the consistent involvement of the PDGFB exon 2. The clinical or histological variations have never been assessed in regards to the COL1A1 breakpoint position. Methods: Using RT-PCR and sequence analysis, we molecularly characterized the COL1A1-PDGFB breakpoints of 35 novel DFSP. We also retrospectively reviewed 137 cases with clinical information and molecular data. Results: In a total of 172 cases of DFSP with molecular data, 38 different exons of COL1A1 were involved in the fusion gene. Exons 25, 29, 32, 40, 46 and 47 were the most frequently involved exons (n>= 10). Eight exons were described in unique cases. Among the 35 new cases analyzed, we identified 3 novel COL1A1 breakpoints involving exons 9, 14 and 39. This study, pooling 172 cases in total, analyzes the largest series of DFSP with molecular data. Analyzing all cases, and with respect to the small number of patients for each group of breakpoints, we have not found any significant correlation between the COL1A1 breakpoint localization and any clinical or histological features. Conclusions: The knowledge of the COL1A1 breakpoint position does not give insights for the patient's care management. In the context of molecular routine diagnosis test, the identification of the COL1A1-PDGFB rearrangement is therefore sufficient, and could be evaluated alternatively by fluorescence in-situ hybridization (FISH). No significant financial relationships to disclose.
Randomized trial with ICE (ifosfamide, carboplatin, etoposide) plus whole body hyperthermia versus ICE chemotherapy for malignant pleural mesothelioma
Authors: A. Bakhahandeh, G. Wiedemann, P. Zabel, K. Dalhoff, T. Kohlmann, R. Zumschlinge, D. Penzel, T. Wagner, S. Peters
Journal: Journal of Clinical Oncology (2004)

7288
Irradiated Donor Leukocytes Promote Engraftment of Allogeneic Bone Marrow in Major Histocompatibility Complex Mismatched Recipients Without Causing Graft-Versus-Host Disease
Authors: Edmund K. Waller, Alan M. Ship, Stephen Mittelstaedt, Timothy W. Murray, Richard Carter, Irina Kakhniashvili, Sagar Lonial, Jeannine T. Holden, Michael W. Boyer
Journal: Blood (1999)
Effectiveness and safety of bevacizumab plus FOLFIRI in first-line metastatic colorectal cancer (mCRC) after 24 months of follow-up for the ETNA cohort study.
Authors: D. Smith, M. Rouyer, Y. Becouarn, P. Michel, R. Guimbaud, N. Tubiana-Mathieu, F. Viret, A. Ravaud, N. Moore, A. Fourrier-Réglat
Journal: Journal of Clinical Oncology (2010)

e14075 Background: Bevacizumab (BV) has been demonstrated to improve survival outcome in mCRC in the pivotal clinical trial (PCT) Hurwitz et al. 2004, and was approved in France in Jan 2005. The ETNA study aimed to describe BV use and survival outcome in real-life practice and to compare results to the PCT. Methods: ETNA is a cohort study conducted in 28 French centers. It included patients (pts) initiating BV from Jan 2006 to Dec 2007. Those treated with BV in first-line mCRC therapy were followed for 24 months. Effectiveness and safety profile for pts receiving BV + FOLFIRI are presented here. Results: Among pts initiating BV, 411 pts had first-line therapy for mCRC: 351 received BV+FOLFIRI and 298 were analyzable after 24 months of follow-up. Their main characteristics were: mean age: 62.9 y, male: 59.1%, ECOG 0-1: 78.9%. 52.7% of pts complied with PCT inclusion criteria for medical data, and 43.3% for laboratory data. Median duration of BV treatment was 5.2 months and median duration of first-line therapy was 9.3 months. 264 pts discontinued first-line treatment: 52 prematurely (due to poor tolerability n = 25; surgical procedure n = 14). The median PFS was 9.5 months (95%CI 9.0- 10.2), the 1-yr overall survival (OS) rate was 78.0% (95%CI 72.9-82.3) and the 2-yr OS rate was 53.4% (95%CI 47.4-59.0). The objective response rate was 58.1%. 21.5% pts had undergone surgery with curative intent, with median time of 209 days from BV initiation to surgery. The incidence of any grade 3/4 adverse event was 48.3% (vs. 85.0% in PCT [BV+IFL]; p < 0.0001): neutropenia (16.1 vs. 37%; p < 0.0001) and diarrhea (11.7 vs. 32%; p < 0.0001). In-line with the known safety profile of BV (any grade), hypertension was observed in 20.1 vs. 22% (p = 0.54), thrombotic events 10.1 vs. 19% (p = 0.001), proteinuria 32.2 vs. 27% (p = 0.13) and GI perforation 0.3 vs. 1.5% (p = 0.11). Conclusions: Results of this cohort complement existing data concerning the BV use in France and demonstrate the effectiveness in mCRC with a large sub-group of pts with BV+FOLFIRI. Safety profile of FOLFIRI regimen seems more manageable than that of IFL regimen. The next step will be to compare these results with those of PCT with multivariate analyses. No significant financial relationships to disclose.
Maximal peritonectomy plus intraperitoneal chemo-hyperthermia (IPCH) in patients with peritoneal carcinomatosis. A single institution experience
Authors: J. Rebollo, P. Bretcha, J. Farre, M. L. Martin, M. Molina, M. Sureda Gonzalez, A. Brugarolas
Journal: Journal of Clinical Oncology (2005)

5168 Background: For most patients (pts), peritoneal carcinomatosis has an ominous prognosis and chemotherapy gives some responses without impact in survival. Recently, extensive peritonectomy plus IPCH has shown promising results with 5-year disease free survival up to 25%. Methods: At our institution, peritonectomy is followed by dextrose 1.5% peritoneal perfusion (open wall) at 0.5–1 l/min perfusion rate extracorporally heated to maintain peritoneal surfaces at 43–44 °C for 90 minutes. Dextrose is admixed with a chemotherapeutic drug (Paclitaxel 60mg/m2 or Mitomycin 10–12.5mg/m2 or Oxaliplatin 460mg/m2, depending on the tumor type). Additional resections are performed if requiered. Results: From June/01 to Oct/04, 33 pts with a median age of 57 years (range 23 to 75 years) have been treated. Sixteen pts had ovarian cancer, 13 pts colorectal cancer, 2 pts gastric cancer and 2 pts endometrial cancer. Almost all pts had been treated previously with surgery and chemotherapy. Median Peritoneal Cancer Index has been 3 (range 0 to 24). A complete resection has been achieved in 31 pts while 3 pts had a incomplete resection. Six patients experienced a prolonged paralytic ileus, abdominal wall abscess 2 pts, urinary tract infection 2 pts, abdominal hemorrage 1 pt and transient renal damage 1 pt. Three pts had severe neutropenia, 2 pts died of sepsis (one in the context of neutropenia and other pt due to anastomotic fistulae). Currently, 15 pts are alive and free of disease, 5 of them after salvage surgery in the thorax (2 pts), abdomen (1 pt) and pelvis (1 pt). Eight pts are living longer than 2 years. Median PFS is 8 months (range 2–37+). MOS has not been achieved with a 63% actuarial 3-year survival. Conclusions: Peritonectomy plus IPCH is a feasible technique that could render a benefit in survival and a chance for cure in carefully selected patients who otherwise have not an alternative option. The program is currently active and new pts are being included. No significant financial relationships to disclose.
Clinical significance of lymphatic/vascular tumor cells (LVT) and adjuvant chemotherapy (AC) after curative resection of non-small cell lung cancer (NSCLC)
Authors: S.-W. Kim, H.-J. Sohn, G.-W. Lee, C. Suh, S.-I. Park, D.-K. Kim, E.-K. Choi, W.-S. Kim, J.-Y. Ro, J.-S. Lee
Journal: Journal of Clinical Oncology (2005)

7044 Background: AC after resection of NSCLC produce only a modest survival benefit. It is needed to find a group who will benefit from AC. Methods: Stage IB-IIIA NSCLC patients (pts) were randomized prospectively either as AC or control (C) group after curative surgery. The AC consisted of 4 cycles of cisplatin 60 mg/m2 (day 1, later changed to day 8) & vinorelbine 25 mg/m2 (day 1 & 8) q 4 weeks, which was started within 4 weeks after surgery (for stage IB) or immediately after postoperative radiotherapy (for stage II, IIIA, 50.4 Gy). C group did not receive AC except postoperative radiotherapy for the stage II, IIIA NSCLC. The end point was to see the disease free survival (DFS) and overall survival (OS) and to find a group who will benefit from AC. The prognostic factors including LVT with hematoxylin/eosin stain were analyzed using Kaplan-Meier plots & the log rank test. Results: From Feb. 2000 to Nov. 2004, 455 pts were enrolled. Gender, age, operative procedure, tumor size (≤ 5 v > 5 Cm), N stage, histology (squamous v non-squamous) and LVT in the pathologic specimen were well balanced between two groups (AC:227, C:228). Two hundred-one pts (44.2%) were stage IB, 150 pts (33.0%) were stage II, and 104 pts (22.8%) were stage IIIA. Ninety-four pts (20.7%) had LVT and the prevalence of LVT was 9% in stage IB, 19.3% in II and 45.2% in IIIA NSCLC. With the median follow up of 27.6 months, the 4-year DFS and OS in AC group and C group were 66.7 v 58.7% (p=0.148) and 67.8 v 61.1% (p=0.503). The log rank test showed that tumor size (> 5Cm), N2 disease, histology with non-squamous type and the presence of LVT were the poor prognostic factors for DFS. Tumor size (> 5Cm), N2 disease, and the presence of LVT were the poor prognostic factors for OS. In the subset analysis, the AC showed significant benefit of DFS (p=0.049) and OS (p=0.060) in the pts with LVT. But the AC could not influence on the DFS or OS of pts without LVT or with other poor prognostic factors. In contrast to other poor prognostic factors, LVT was not the poor prognostic factor for DFS in AC group. Conclusions: The presence of LVT in the surgical specimen is an important prognostic factor after resection of NSCLC and could be overcome by AC in the aspect of DFS and OS. No significant financial relationships to disclose.
BRSK2 expression as a prognosis marker in pancreatic cancer patients
Authors: W. Lou Dr., G. Niu
Journal: Journal of Clinical Oncology (2009)

e15603 Background: The prognosis of pancreatic cancer remains dismal because of difficult early diagnosis, low resection rate and aggressive biological behavior. The research of factors related to oncogenesis, tumor infiltration and metastasis is valuable. AMPK(AMP-activated protein kinase)family is a group of regulators on the cellular energy metabolism which are sensitive to the cytoplasmic change of AMP/ATP ratio. As a member of AMPK, BRSK2 is found to be expressed in human pancreatic cell line and facilitate the tumor cell survival on glucose starving. In order to examine the expression of BRSK2 in human pancreatic cancer and explore the underline clinical implication, human pancreatic tissue was examined immunohistochemically Correlation of tumor biological behavior, prognosis and BRSK2 expression was examined. Methods: Seventy nine resected tumor specimens were collected. Immunochemical staining method was used to examine the expression pattern of BRSK2 translated protein. Semi-quantitative analysis was employed to compare the expression intensity and content of BRSK2 in tumor issues, peri-tumorous tissue and normal pancreatic tissue. Possible relationship of tumors differentiation, TNM stage, presence or absence of vessel and neural infiltration were explored with BRSK2 expression. The correlation of BRSK2 expression profile and patients survival was explored. Results: BRSK2 was weakly expressed in normal pancreatic tissues and peri-tumor tissues, including the islet and minor ducts. BRSK2 was strongly expressed in pancreatic cancer tissues, the expression intensity was correlated with extent of lymphatic metastasis, distant metastasis, TNM staging and neural invasion. Tumors with lymphatic metastasis, distant metastasis, neural invasion and later TNM stages showed stronger expression of BRSK2. The expression of BRSK2 in pancreatic cancer was closely correlated to the prognosis of patients, those with higher expression pattern showed bad prognosis. Conclusions: BRSK2 is up-regulated in pancreatic cancer; the expression of BRSK2 is correlated with tumor biological behavior and patient's prognosis. No significant financial relationships to disclose.
A dose and time response analysis of the treatment of Hodgkin's disease with MOPP chemotherapy.
Authors: P Carde, F R MacKintosh, S A Rosenberg
Journal: Journal of Clinical Oncology (1983)

A dose-response analysis of the results of MOPP chemotherapy in 132 patients with Hodgkin's disease was carried out. Complex statistical methods were utilized including 40 different dose-time variables and multivariate logistic analyses of 21 clinical variables, both simply and in stepwise regression. These covariates were not independent, and in stepwise regression analysis only B-symptoms and the mean three-cycle rate of drug delivery significantly influenced complete remission attainment. Two parameters, bone marrow involvement (negative) and lung involvement (positive), significantly influenced the duration of complete remission. Survival was influenced adversely by pleural involvement (effusion), advanced age, and B-symptoms. Analyses indicate that the dose of all three drugs (mustard, vincristine, and procarbazine), and the rate of drug delivery during the first three cycles are important in achieving maximal complete response rates, especially for patients with B-symptoms.
A Patient With Blue Ears
Authors: Kayria Muttardi, Alan Rubin, Victoria L. Brown
Journal: JAMA Dermatology (2016)

A 65-year-old woman presented with a 5-year history of increasing blue discoloration of her ears; she had mild knee arthralgia and was seeing an ophthalmologist annually regarding brown spots on both eyes diagnosed as conjunctival nevi. What is your diagnosis?